National Team Enters AI Virtual Cells, 'Baiyao Technology' Completes New Round of Financing Tens of Millions of Yuan | 36Kr Exclusive
Baiyao Technology's securing of tens of millions in financing led by China Reform Holdings may appear on the surface as an inevitable outcome of a booming sector and a strong team, but at its core, it resembles a precisely timed signal flare: the seemingly ultra-sci-fi competition of AI Virtual Cells (AIVC) has officially transitioned from "scientists' paper concepts" into the "range of state-backed capital" on the Chinese track.
Analysis
Where the money comes from often reveals more than where it goes. China Reform Holdings is a national-level state-owned capital operating platform. Its role as the lead investor elevates this beyond a typical VC bet on a trend—it constitutes a "stamped certification" with strategic undertones. What it's investing in is not merely Baiyao Technology as a specific company, but a crucial layer on the grand map of "AI + Life Sciences": cell-level simulation. This marks a fundamental divergence from the previous logic of flocking to AI-driven pharmaceutical development and molecular screening. The latter is akin to optimizing paths on an existing map, whereas AIVC attempts to redraw the underlying map of life systems itself. China Reform's entry effectively signals national-level recognition of the strategic reserve value of this "map-redrawing" capability.
However, amidst the excitement, a cold shower of reality is necessary: the gap between a "model with second-best global predictions" in the lab and "precise predictions of drug toxicity" on the production line is not a small ditch, but a canyon filled with data black holes, validation challenges, and an industry cognition chasm. Baiyao team's academic credentials are impeccable, from the Institute of Zoology of the Chinese Academy of Sciences to cover articles in Cell Research, and their technical narrative is polished. But scientific "polish" and commercial "usability" are two different things. The core promise of AIVC is "model-driven R&D," replacing the traditional "experiment-driven" approach. This sounds revolutionary, but anyone with basic respect for biological experiments would ask: on what basis? Why believe that a digital cell trained on public omics data can truly simulate the complex, chaotic, and individually variable real cell systems within the human body? "Hallucinations" in models mean nonsense in the linguistic domain; in life sciences, they could mean tens of billions of dollars in trial-and-error.
This raises an even sharper question: how much of the current heat in the AIVC track stems from solid technological conviction, and how much is a concept premium manufactured by capital seeking the "next grand narrative" in the post-AI drug discovery era? With AI applications at the molecular level already crowded into a red ocean, investors urgently need a new, more disruptive-sounding story to maintain market excitement. "Cell-level simulation" perfectly fits the bill—it's grand, deep, distant, and inspires imagination. Consequently, we see the passionate vocabulary in investor viewpoints: "disruptive," "most imaginative space." In venture capital, these words are stimulants. But on the long march of technological implementation, they should more appropriately serve as a ruler to constantly measure the distance between reality and imagination.
Baiyao Technology mentioned building a "data closed loop," where models, self-generated data, and application scenarios mutually reinforce each other. This is the correct direction, but also the toughest nut to crack. High-quality, continuous, perturbation-responsive time-series cellular data is the oil for AIVC, and such data is currently extremely scarce and expensive. Their plan to launch a self-generated dataset platform is undoubtedly playing their hardest, heaviest move. Without this, all models are castles in the air. But building such a platform—its cost, complexity, and time required—may far exceed the surface figure of the financing. These tens of millions might be enough to drill a deep well, but the distance to building a continuously producing oil field is still vast.
Therefore, this financing is more a serious beginning than a victory fanfare. It marks AIVC's transition from an endeavor for geeks to an important piece on the chessboard. But whether that piece can become an ace depends on every subsequent step: whether the model withstands repeated crucifixion in wet-lab experiments, whether the data flywheel can truly spin, and whether the team can withstand the strategic demands and time pressure that may accompany the "national team" capital without being derailed by the market's inflated valuation expectations.
The real contest has only just begun. Baiyao Technology stands at an excellent starting position, but the track ahead is half imagination of a vast future and half the harsh reality of muddy, bumpy terrain. What it needs is not just algorithms and data, but a nearly obsessive engineering capability and industrial patience that can keep its feet firmly on the ground while gazing at the stars. After all, in the field of life sciences, the end of any shortcut is often a longer detour.
Disclaimer: The above content is generated by AI and is for reference only.